Zoledronic Acid
It is a bisphosphonic acid that is an inhibitor of osteoclastic bone resorption.Hypercalcemia of malignancy. Multiple myeloma. Bone metastases from solid tumors.
Administration: 4mg is diluted in 100ml of sterile 0.9% Nacl or 5% dextrose injection for intravenous infusion over no less than 15-minutes.Administration: 4mg is diluted in 100ml of sterile 0.9% Nacl or 5% dextrose injection for intravenous infusion over no less than 15-minutes. Hypercalcemia of malignancy/tumor induced hypercalcemia (albumin-corrected serum calcium ³ 12mg/dL): 4mg as a single dose. If required repeat the initial dose after minimum of 7-days interval. Multimyelona and metasta
Hypersensitivity. Serve renal impairment.
Monitor serum creatinine, calcium, electrolytes, phosphate, magnesium and hematocrit/haemoglobin. Adequately rehydrate the patient before treatment. Hepatic insufficiency. Asthma (aspirin sensitive). Paediatric : Safety and efficacy is not established. Pregnancy : Not recommended. Lactation : Safety is not established. Elderly : Safe but monitor renal function.
Common : Pancytopenia, confusion, nausea, flue-like syndrome, fatigue, arthaligia, bradycardia, creatinine, level, elevations, fever, thirst, hypercalcemia, taste perversion. Uncommon : Thrombocytopenia, conjunctivitis, vomiting, skeletal pain, chest pain, hypophosphataemia, hypomagnesaemia, headache, pruritus, rash. Rare : Local reactions at infusion site. Very rare : Acute renal failure
Increased risk of hypocalcemia when used in combination with loop diuretics. Risk of renal dysfunction may be increased when used in combiantion with thalidomide.
